OMB
APPROVAL
|
OMB Number:
3235-0070
|
Expires:
October 30, 2009
|
Estimated average burden
hours per response: ……………….192
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-Q
(Mark One)
|
|
X
|
|
QUARTERLY REPORT UNDER SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
For the quarter
period ended
March 31, 2009
|
|
|
|
TRANSITION REPORT UNDER SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
For the transition period
from___________ to __________
|
|
Commission file number
000-52331
|
MOLECULAR
PHARMACOLOGY (USA) LIMITED
|
(Exact name of registrant
as specified in its charter)
|
NEVADA
|
|
71-0900799
|
(State or other
jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
Drug Discovery Centre
284 Oxford Street, Leederville 6007 Perth, Western Australia
|
(Address of principal
executive offices)
|
011-61-8-9443-3011
|
(Registrant’s
telephone number including area code)
|
Not Applicable
|
(Former name, former
address and formal fiscal year, if changed since last report)
|
Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the
Exchange Act during the past 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
|
Yes
x
|
No
o
|
|
Indicate by check mark whether the registrant is
large accelerated filer, an accelerated filer, a non accelerated filer, or a
small reporting company. See the definitions of “large accelerated
filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act (Check one):
|
Large Accelerated Filer
o
|
Accelerated Filer
|
Non-Accelerated Filer
o
|
Smaller Reporting Company
x
|
Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act)
|
Yes
x
|
No
o
|
Indicate by check mark whether the registrant has
filed all documents and reports required to be filed by Section 12, 13 and
15(d) of the Securities Exchange Act of 1934 subsequent to the distribution
of securities under a plan confirmed by a court
|
|
Yes
x
|
No
o
|
State the number of
shares outstanding of each of the issuer’s classes of common equity, as
of the latest practicable date.
|
111,553,740
common shares issued and outstanding as of April 30, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
i
MOLECULAR
PHARMACOLOGY (USA) LIMITED
Form 10-Q
March 31, 2009
Table of Contents
PART I – FINANCIAL INFORMATION
|
|
Item 1.
|
Financial Statements
|
1
|
Item 2.
|
Management Discussion and Analysis of Financial Condition and Results
of Operation
|
18
|
Item 3.
|
Quantitative and Quantitative Disclosures About Market Risk
|
27
|
Item 4.
|
Controls and Procedures
|
27
|
|
|
|
PART II – OTHER INFORMATION
|
|
|
|
|
Item 1.
|
Legal Proceedings
|
29
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
29
|
Item 3.
|
Defaults Upon Senior Securities
|
29
|
Item 4.
|
Submission of Matters to a Vote of Security Holders
|
29
|
Item 5.
|
Other Information
|
29
|
Item 6.
|
Exhibits and Reports on Form 10-Q
|
29
|
|
|
|
SIGNATURES
|
30
|
ii
PART 1 - FINANCIAL INFORMATION
Item 1. Financial Statements
The
information in this report for the nine months ended March 31, 2009, is
unaudited but includes all adjustments (consisting only of normal recurring
accruals, unless otherwise indicated) which Molecular Pharmacology (USA)
Limited ("
Molecular USA
" or the "
Company
") considers necessary for a fair presentation
of the financial position, results of operations, changes in stockholders'
equity and cash flows for those periods.
The
financial statements should be read in conjunction with Molecular USA’s
financial statements and the notes thereto contained in Molecular USA's Audited
Financial Statements for the year ended June 30, 2008, in the Form 10KSB filed
with the SEC on October 2, 2008.
Interim
results are not necessarily indicative of results for the full fiscal year.
The
unaudited financial statements start on the next page.
1
Molecular Pharmacology (USA)
Limited
(A Development Stage Company)
Interim Consolidated Financial
Statements
(Expressed
in U.S. Dollars)
(Unaudited)
31 March 2009
2
Molecular Pharmacology (
USA
) Limited
(A Development Stage
Company)
Interim Consolidated Balance Sheets
(Expressed in U.S. Dollars)
(Unaudited)
|
|
As at
31 March
2009
|
|
As at
30 June
2008
(Audited)
|
|
|
$
|
|
$
|
Assets
|
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
Cash and cash
equivalents
|
|
4,673
|
|
21,490
|
Amounts
receivable
|
|
3,244
|
|
9,396
|
|
|
|
|
|
|
|
7,917
|
|
30,886
|
|
|
|
|
|
Property,
plant and equipment
(Note 3)
|
|
3,147
|
|
3,712
|
|
|
|
|
|
|
|
11,064
|
|
34,598
|
Liabilities
|
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
Accounts payable and
accrued liabilities (Note 4)
|
|
12,858
|
|
26,266
|
|
|
|
|
|
Due
to related parties
(Note 5)
|
|
1,059,540
|
|
1,424,159
|
|
|
|
|
|
|
|
1,072,398
|
|
1,450,425
|
|
|
|
|
|
Stockholders’
deficiency
|
|
|
|
|
Capital
stock
(Note 6)
|
|
|
|
|
Authorized
|
|
|
|
|
300,000,000 of
common shares, par value $0.001
|
|
|
|
|
Issued and
outstanding
|
|
|
|
|
31 March 2009
– 111,553,740 common shares, par value $0.001
|
|
|
|
|
30 June 2008 – 111,553,740 common shares,
par value $0.001
|
|
111,554
|
|
111,554
|
Additional
paid-in capital
|
|
106,707
|
|
106,707
|
Cumulative
translation adjustment
|
|
112,206
|
|
(294,838)
|
Deficit,
accumulated during the development stage
|
|
(1,391,801)
|
|
(1,339,250)
|
|
|
|
|
|
|
|
(1,061,334)
|
|
(1,415,827)
|
|
|
|
|
|
|
|
11,064
|
|
34,598
|
Nature and
Continuance of Operations
(Note
1) and
Commitment
(Note 8)
On behalf of the Board:
/s/ Jeffrey
Edwards
Director
Jeffrey Edwards
3
Molecular
Pharmacology (USA)
Limited
A
Development Stage Company)
Interim Consolidated Statements of Operations
(Expressed in U.S. Dollars)
(Unaudited)
|
For the
period
from
the
date of inception
on
14 July
2004
to
31
March
2009
|
For the
three
month
period
ended
31
March
2009
|
For the
three
month
period
ended
31
March
2008
|
For the
nine
month
period
ended
31
March
2009
|
For the
nine
month
period
ended
31
March
2008
|
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
Advertising and promotion
|
|
23,739
|
|
-
|
|
-
|
|
-
|
|
-
|
Analysis
|
|
33,947
|
|
-
|
|
-
|
|
-
|
|
-
|
Consulting (Note 5)
|
|
1,083,458
|
|
7,935
|
|
11,798
|
|
23,765
|
|
66,300
|
Depreciation
|
|
4,700
|
|
202
|
|
365
|
|
676
|
|
1,077
|
Office and miscellaneous (Note 5)
|
|
140,883
|
|
3,279
|
|
6,675
|
|
17,230
|
|
25,219
|
Professional fees
|
|
199,857
|
|
4,311
|
|
8,446
|
|
28,175
|
|
45,536
|
Public relations
|
|
3,656
|
|
-
|
|
-
|
|
-
|
|
565
|
Rent
|
|
27,759
|
|
-
|
|
-
|
|
-
|
|
-
|
Salaries and
benefits
|
|
44,464
|
|
-
|
|
-
|
|
-
|
|
-
|
Transfer agent and
filing fees
|
|
9,943
|
|
1,359
|
|
-
|
|
4,511
|
|
1,889
|
Travel
|
|
104,240
|
|
(86)
|
|
2,036
|
|
1,674
|
|
6,846
|
|
|
|
|
|
|
|
|
|
|
|
Net loss before other items
|
|
(1,676,646)
|
|
(17,000)
|
|
(29,320)
|
|
(76,031)
|
|
(147,432)
|
|
|
|
|
|
|
|
|
|
|
|
Other items
|
|
|
|
|
|
|
|
|
|
|
Export market development grants
|
|
69,594
|
|
6,420
|
|
-
|
|
6,420
|
|
-
|
Interest income
|
|
2,322
|
|
-
|
|
-
|
|
-
|
|
-
|
Research and development tax refund
|
|
212,929
|
|
10,309
|
|
935
|
|
17,060
|
|
69,092
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period
|
|
(1,391,801)
|
|
(271)
|
|
(28,385)
|
|
(52,551)
|
|
(78,340)
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per common share
|
|
|
|
(0.001)
|
|
(0.001)
|
|
(0.001)
|
|
(0.001)
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares used in
per share calculations
|
|
|
|
111,553,740
|
|
111,553,740
|
|
111,553,740
|
|
111,553,740
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period
|
|
(1,391,801)
|
|
(271)
|
|
(28,385)
|
|
(52,551)
|
|
(78,340)
|
Foreign currency translation adjustment
|
|
112,206
|
|
201,305
|
|
(64,553)
|
|
407,044
|
|
(107,173)
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income (loss) for the period
|
|
(1,279,595)
|
|
201,034
|
|
(92,938)
|
|
354,493
|
|
(185,513)
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income (loss) per common share
|
|
|
|
0.002
|
|
(0.001)
|
|
0.003
|
|
(0.002)
|
|
|
|
|
|
|
|
|
|
|
|
4
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Interim
Consolidated Statements of Cash Flows
(Expressed in U.S. Dollars)
(Unaudited)
|
For the
period
from
the
date of
inception on 14
July 2004
to
31
March
2009
|
For the
nine
month
period
ended
31
March
2009
|
For the
nine
month
period
ended
31
March
2008
|
|
|
$
|
|
$
|
|
$
|
|
|
|
|
|
|
|
Cash
flows from (used in) operating activities
|
|
|
|
|
|
|
Net income for the period
|
|
(1,391,801)
|
|
(52,551)
|
|
(78,340)
|
Adjustments to reconcile loss to net cash used by
operating activities
|
|
|
|
|
|
|
Depreciation
(Note 3)
|
|
4,700
|
|
676
|
|
1,077
|
Write-down of
intangible assets
|
|
1,278
|
|
-
|
|
-
|
Changes in
operating assets and liabilities
|
|
|
|
|
|
|
(Increase) decrease in amounts receivable
|
|
(1,018)
|
|
6,152
|
|
14,418
|
Decrease in accounts payable and accrued liabilities
(Note 4)
|
|
(41,767)
|
|
(13,408)
|
|
(31,764)
|
|
|
|
|
|
|
|
|
|
(1,428,608)
|
|
(59,131)
|
|
(94,609)
|
|
|
|
|
|
|
|
Cash
flows from (used in) investing activities
|
|
|
|
|
|
|
Purchase of property, plant and equipment (Note 3)
|
|
(7,847)
|
|
(111)
|
|
17
|
Purchase of intangible
assets
|
|
(1,278)
|
|
-
|
|
-
|
Cash acquired on
the purchase of Molecular Pharmacology (USA) Limited (Note 1)
|
|
37,163
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
28,038
|
|
(111)
|
|
17
|
|
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
Common shares issued for cash (Note 6)
|
|
234,497
|
|
-
|
|
-
|
Increase (decrease) in due to related parties (Note
5)
|
|
1,058,540
|
|
(364,619)
|
|
215,917
|
|
|
|
|
|
|
|
|
|
1,293,037
|
|
(364,619)
|
|
215,917
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash
|
|
112,206
|
|
407,044
|
|
(107,173)
|
|
|
|
|
|
|
|
Increase in cash and cash equivalents
|
|
4,673
|
|
(16,817)
|
|
14,152
|
|
|
|
|
|
|
|
Cash
and cash equivalents, beginning of period
|
|
-
|
|
21,490
|
|
20,994
|
|
|
|
|
|
|
|
Cash
and cash equivalents, end of period
|
|
4,673
|
|
4,673
|
|
35,146
|
Supplemental
Disclosures with Respect to Cash Flows
(Note
9)
5
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Interim Consolidated Statements of Changes in Stockholders’ Deficiency
(Expressed in U.S. Dollars)
(Unaudited)
|
Number
of common shares issued
|
Capital stock
|
Additional paid-in capital
|
Deficit, accumulated during the
development stage
|
Cumulative translation adjustment
|
Stockholders’ deficiency
|
|
|
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
Balance at 14 July 2004 (inception)
|
|
294
|
|
-
|
|
1
|
|
-
|
|
-
|
|
1
|
Net loss for the
period
|
|
-
|
|
-
|
|
-
|
|
(128,488)
|
|
-
|
|
(128,488)
|
Cumulative
translation adjustment
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(6,536)
|
|
(6,536)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at 31 October 2004
|
|
294
|
|
-
|
|
1
|
|
(128,488)
|
|
(6,536)
|
|
(135,023)
|
Common shares
issued for cash – January 2005
|
|
87,999,706
|
|
88,000
|
|
146,496
|
|
-
|
|
-
|
|
234,496
|
Net loss for the
year
|
|
-
|
|
-
|
|
-
|
|
(387,667)
|
|
-
|
|
(387,667)
|
Cumulative
translation adjustment
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(161)
|
|
(161)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at 31 October 2005
|
|
88,000,000
|
|
88,000
|
|
146,497
|
|
(516,155)
|
|
(6,697)
|
|
(288,355)
|
Acquisition of Molecular
Pharmacology (USA)
Limited – Recapitalization May 2006
|
|
43,553,740
|
|
43,554
|
|
(59,790)
|
|
-
|
|
-
|
|
(16,236)
|
Cancellation of common
shares – July 2006 (Note 6)
|
|
(20,000,000)
|
|
(20,000)
|
|
20,000
|
|
-
|
|
-
|
|
-
|
Net loss for the year
|
|
-
|
|
-
|
|
-
|
|
(508,260)
|
|
-
|
|
(508,260)
|
Cumulative translation adjustment
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(16,222)
|
|
(16,222)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at 31 October 2006
|
|
111,553,740
|
|
111,554
|
|
106,707
|
|
(1,024,415)
|
|
(22,919)
|
|
(829,073)
|
Net loss for the period
|
|
-
|
|
-
|
|
-
|
|
(377,131)
|
|
-
|
|
(377,131)
|
Cumulative translation
adjustment
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(105,436)
|
|
(105,436)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at 30 June 2007
|
|
111,553,740
|
|
111,554
|
|
106,707
|
|
(1,401,546)
|
|
(128,355)
|
|
(1,311,640)
|
Net income for the year
|
|
-
|
|
-
|
|
-
|
|
62,296
|
|
-
|
|
62,296
|
Cumulative translation
adjustment
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(166,483)
|
|
(166,483)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at 30 June 2008
|
|
111,553,740
|
|
111,554
|
|
106,707
|
|
(1,339,250)
|
|
(294,838)
|
|
(1,415,827)
|
Net loss for the
period
|
|
-
|
|
-
|
|
-
|
|
(52,551)
|
|
-
|
|
(52,551)
|
Cumulative
translation
adjustment
|
|
-
|
|
-
|
|
-
|
|
-
|
|
407,044
|
|
407,044
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at 31 March 2009
|
111,553,740
|
|
111,554
|
|
106,707
|
|
(1,391,801)
|
|
112,206
|
|
(1,061,334)
|
6
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Notes
to Interim Consolidated Financial Statements
(Expressed
in U.S. Dollars)
(Unaudited)
31 March
2009
1.
Nature and Continuance of Operations
Molecular Pharmacology (USA) Limited (the “Company”) was
incorporated in the state of Nevada
on 1 May 2002 under the name Blue Hawk Ventures, Inc. The Company changed its name to
Molecular Pharmacology (USA) Limited on 29 August 2005. At the same time, the Company completed
a four for one forward split of its issued and outstanding share capital and
altered its share capital to 300,000,000 shares of common stock with a par
value of $0.001 per share.
The Company is a development stage enterprise, as defined in Statements
of Financial Accounting Standards (“SFAS”) No. 7, “
Accounting and Reporting by Development Stage Enterprises
”. The Company is devoting all of its
present efforts to securing and establishing a new business and its current
planned principle operations have not commenced. Accordingly, no revenue has been derived
during the organization period.
Up until the fall of 2005, the Company was in the business of mineral
exploration and development of a mineral property. The Company allowed the option on its
mineral claim to lapse in the fall of 2005.
On 13 October 2005, the Company entered into a distribution and supply
agreement (the “Distribution Agreement”) with Molecular
Pharmacology Limited (“MPLA”).
MPLA is incorporated under the laws of Australia and is a wholly owned
subsidiary company of PharmaNet Group Limited (“PharmaNet”), an Australian company listed on the Australian
Stock Exchange. Under the terms of
the distribution and supply agreement, the Company has the exclusive
distribution rights to distribute, market, promote, detail, advertise and sell
certain “Licensed Products”, as defined in the agreement (Note 8).
Since signing the Distribution Agreement with MPLA, the Company has
engaged in organizational and start up activities, including developing a new
business plan, recruiting new directors, scientific advisors and key
scientists, making arrangements for laboratory facilities and office space and
raising additional capital. The
Company has generated no revenue from product sales. The Company does not have any
pharmaceutical products currently available for sale, and none are expected to
be commercially available for some time, if at all. The Licensed Products must first undergo
pre-clinical and human clinical testing in the United States before they may be
sold commercially.
The Company completed a share purchase agreement on 8 May 2006 with
PharmaNet. Under the terms of the
agreement the Company acquired 100% of the issued and outstanding shares of
MPLA (the “Purchase Agreement”). The Company, in exchange for 100% of the
issued and outstanding shares of MPLA, issued PharmaNet an aggregate total of
88,000,000 shares of its common shares of the Company on the closing of the
transaction. The issuance of
88,000,000 common shares of the Company constituted an acquisition of control
of the Company by PharmaNet. The
transaction has been accounted for as a recapitalization of the Company (Note
2).
MPLA was incorporated on 14 July 2004 under the laws of Australia. The accompanying financial statements
are the historical financial statements of MPLA.
7
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Notes to Interim Consolidated Financial Statements
(Expressed in U.S. Dollars)
(Unaudited)
31
March 2009
On 15 March 2007, the Board of Directors approved a change in the
Company’s financial year end from 31 October to 30 June. The decision to
change the fiscal year end was intended to assist the financial community in
its analysis of the business and in comparing the Company’s financial
results to others in the industry, and to synchronize the Company’s
fiscal reporting with MPLA.
The Company’s
consolidated financial statements as at 31 March 2009 and for the nine month
period then ended have been prepared on a going concern basis, which
contemplates the realization of assets and settlement of liabilities and
commitments in the normal course of business. The Company has a net loss of $52,551
for the nine month period ended 31 March 2009 (nine month period ended 31 March
2008 –$
78,340)
and has a working capital deficit of $4,941 at 31 March 2009 (30 June 2008
– working capital of $4,620).
Management cannot provide assurance that the Company will ultimately
achieve profitable operations or become cash flow positive, or raise additional
debt and/or equity capital.
Management believes that the Company’s capital resources should be
adequate to continue operating and maintaining its business strategy during the
fiscal year ending 30 June 2009.
However, if the Company is unable to raise additional capital in the
near future, due to the Company’s liquidity problems, management expects
that the Company will need to curtail operations, liquidate assets, seek
additional capital on less favorable terms and/or pursue other remedial
measures. These consolidated financial
statements do not include any adjustments related to the recoverability and
classification of assets or the amounts and classification of liabilities that
might be necessary should the Company be unable to continue as a going concern.
At 31 March 2009, the Company has suffered losses from development
stage activities to date. Although
management is currently attempting to implement its business plan, and is
seeking additional sources of equity or debt financing, there is no assurance
these activities will be successful.
These factors raise substantial doubt about the ability of the Company
to continue as a going concern. The
consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.
2.
Significant Accounting Policies
The following is a summary of significant
accounting policies used in the preparation of these consolidated financial
statements.
Basis of presentation
These interim consolidated financial statements have been prepared in
accordance with generally accepted accounting principles in the United States of America
(“U.S. GAAP”) applicable for a developmental stage company for
financial information and are expressed in U.S. dollars.
Basis of consolidation
These consolidated financial statements include the accounts of MPLA
since its incorporation on 14 July 2004 and MPLA USA since the reverse acquisition
on 8 May 2006 (Note 1). All
intercompany balances and transactions have been eliminated.
8
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Notes to Interim Consolidated Financial Statements
(Expressed in U.S. Dollars)
(Unaudited)
31
March 2009
Cash and cash equivalents
Cash and cash equivalents include highly liquid
investments with original maturities of three months or less.
Financial instruments
The carrying value of cash and cash equivalents, amounts receivable,
accounts payable and accrued liabilities and due to related parties
approximates their fair value because of the short maturity of these
instruments. The Company’s
operations are in Australia
and virtually all of its assets and liabilities give rise to significant
exposure to market risks from changes in foreign currency rates. The Company’s financial risk is
the risk that arises from fluctuations in foreign exchange rates and the degree
of volatility of these rates. Currently,
the Company does not use derivative instruments to reduce its exposure to
foreign currency risk.
Foreign currency translation
The consolidated financial statements of the Company are translated to
U.S. dollars in accordance with SFAS No. 52, “
Foreign
Currency Translation
”.
Assets and liabilities denominated in foreign currencies are translated
using the exchange rate prevailing at the balance sheet date. Revenue and expenses are translated at
average rates of exchange prevailing during the year. Translation adjustments
resulting from this process are charged or credited to Other Comprehensive
Income
.
The Company has not, to the date of these consolidated
financial statements, entered into derivative instruments to offset the impact
of foreign currency fluctuations.
Derivative financial instruments
The Company has not, to the date of these consolidated financial
statements, entered into derivative instruments to offset the impact of foreign
currency fluctuations.
Property, plant and equipment
Property, plant and equipment are recorded at
cost and depreciation is provided over their estimated economic lives at the
following rates:
|
Office
equipment
|
15%
declining balance
|
Income taxes
Deferred income taxes are reported for timing differences between items
of income or expense reported in the financial statements and those reported
for income tax purposes in accordance with SFAS No. 109, “
Accounting for Income Taxes
”, which requires the use
of the asset/liability method of accounting for income taxes. Deferred income taxes and tax benefits
are recognized for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and
liabilities and their respective tax bases, and for tax loss and credit carry
forwards.
9
Molecular Pharmacology (USA)
Limited
(A Development Stage Company)
Notes to Interim Consolidated Financial Statements
(Expressed in U.S. Dollars)
(Unaudited)
31
March 2009
Deferred tax assets and liabilities are measured using enacted tax rates
expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The Company provides for deferred taxes
for the estimated future tax effects attributable to temporary differences and
carry-forwards when realization is more likely than not.
Comprehensive loss
SFAS No. 130, “
Reporting
Comprehensive Income
”,
establishes standards for the reporting and display of comprehensive loss and
its components in the financial statements. As at 31 March 2009, the Company has
items that represent a comprehensive loss and, therefore, has included a
schedule of comprehensive loss in the consolidated financial statements.
Basic and diluted net loss per share
The Company computes net loss per share in accordance with SFAS No.
128, “
Earnings per Share
”. SFAS No. 128 requires presentation of
both basic and diluted earnings per share (“EPS”) on the face of
the income statement. Basic EPS is
computed by dividing net loss available to common shareholders (numerator) by
the weighted average number of shares outstanding (denominator) during the
period. Diluted EPS gives effect to
all potentially dilutive common shares outstanding during the period using the
treasury stock method and convertible preferred stock using the if-converted
method. In computing diluted EPS,
the average stock price for the period is used in determining the number of
shares assumed to be purchased from the exercise of stock options or
warrants. Diluted EPS excludes all
potentially dilutive shares if their effect is anti-dilutive.
Stock-based compensation
Effective 1 February 2006, the Company adopted the provisions
of SFAS No. 123(R), “
Share-Based Payment
”,
which establishes accounting for equity instruments exchanged for employee
services. Under the provisions of
SFAS 123(R), stock-based compensation cost is measured at the grant date, based
on the calculated fair value of the award, and is recognized as an expense over
the employees’ requisite service period (generally the vesting period of
the equity grant). Before 1 February 2006,
the Company accounted for stock-based compensation to employees in accordance
with Accounting Principles Board Opinion No. 25, “
Accounting for Stock Issued to Employees
”, and
complied with the disclosure requirements of SFAS No. 123, “
Accounting for Stock-Based Compensation
”. The
Company adopted FAS 123(R) using the modified prospective method, which
requires the Company to record compensation expense over the vesting period for
all awards granted after the date of adoption, and for the unvested portion of
previously granted awards that remain outstanding at the date of adoption. Accordingly, financial statements for
the periods prior to 1 February 2006 have not been restated to reflect the fair
value method of expensing share-based compensation. Adoption of SFAS No. 123(R) does
not change the way the Company accounts for share-based payments to
non-employees, with guidance provided by SFAS 123 (as originally issued) and
Emerging Issues Task Force Issue No. 96-18, “
Accounting
for Equity Instruments That Are Issued to Other Than Employees for Acquiring,
or in Conjunction with Selling, Goods or Services
”.
10
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Notes to Interim Consolidated Financial Statements
(Expressed in U.S. Dollars)
(Unaudited)
31
March 2009
Recent accounting pronouncements
In
May 2008, the
Financial
Accounting Standards Board (the “FASB”) issued SFAS No. 163,
Accounting for Financial Guarantee Insurance Contracts – an
interpretation of FASB Statement No. 60 (“SFAS No. 163”). SFAS No. 163 provides enhanced guidance
on the recognition and measurement to be used to account for premium revenue
and claim liabilities and related disclosures and is limited to financial
guarantee insurance (and reinsurance) contracts, issued by enterprises included
within the scope of FASB Statement No. 60, Accounting and Reporting by
Insurance Enterprises. SFAS No. 163
also requires that an insurance enterprise recognize a claim liability prior to
an event of default when there is evidence that credit deterioration has
occurred in an insured financial obligation. SFAS No. 163 is effective for financial
statements issued for fiscal years and interim periods beginning after 15
December 2008, with early application not permitted. The Company does not expect SFAS No. 163
to have an impact on its consolidated financial statements.
In May 2008, the FASB issued SFAS No. 162, The Hierarchy of Generally
Accepted Accounting Principles (“SFAS No. 162”). SFAS No. 162 is intended to improve
financial reporting by identifying a consistent framework, or hierarchy, for
selecting accounting principles to be used in preparing financial statements
that are presented in conformity with U.S. Generally Accepted Accounting
Principles (“GAAP”) for nongovernmental entities. Prior to the issuance of SFAS No. 162,
GAAP hierarchy was defined in the American Institute of Certified Public
Accountants (“AICPA”) Statement on Auditing Standards No. 69, The
Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles
(“SAS No. 69”). SAS No.
69 has been criticized because it is directed to the auditor rather than the
entity. SFAS No. 162 addresses
these issues by establishing that the GAAP hierarchy should be directed to
entities because it is the entity, not its auditor, that is responsible for
selecting accounting principles for financial statements that are presented in
conformity with GAAP. SFAS No. 162
is effective 60 days following the SEC’s approval of the Public Company
Accounting Oversight Board Auditing amendments to AU Section 411, The Meaning
of Present Fairly in Conformity with Generally Accepted Accounting
Principles. The Company does not
expect SFAS No. 162 to have a material effect on its consolidated financial statements.
In March 2008, the FASB issued SFAS No. 161, Disclosures about
Derivative Instruments and Hedging Activities – an amendment of FASB
Statement No. 133 (“SFAS No. 161”). SFAS No. 161 is intended to improve
transparency in financial reporting by requiring enhanced disclosures of an
entity’s derivative instruments and hedging activities and their effects
on the entity’s financial position, financial performance, and cash
flows. SFAS No. 161 applies to all
derivate instruments within the scope of SFAS No. 133, Accounting for
Derivative Instruments and Hedging Activities (“SFAS No.
133”). It also applies to
non-derivative hedging instruments and all hedged items designated and
qualifying as hedges under SFAS No. 133.
SFAS No. 161 is effective prospectively for financial statements issued
for fiscal years beginning after 15 November 2008, with early application
encouraged. The Company is
currently evaluating the new disclosure requirements of SFAS No. 161 and the
potential impact on the Company’s consolidated financial statements.
11
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Notes to Interim Consolidated Financial Statements
(Expressed in U.S. Dollars)
(Unaudited)
31
March 2009
In December 2007,
the FASB
issued SFAS No. 141 (revised 2007),
Business Combinations (“SFAS No. 141(R)”). SFAS No. 141(R)
establishes principles and requirements for how an acquirer recognizes and
measures in its financial statements the identifiable assets acquired, the
liabilities assumed, any noncontrolling interest in the acquiree and the goodwill
acquired. SFAS No. 141(R) also establishes disclosure requirements to enable
the evaluation of the nature and financial effects of the business combination.
SFAS No. 141(R) is effective for fiscal years beginning after 15 December 2008. The Company is currently evaluating the
potential impact, if any, of the adoption of SFAS No. 141(R) on its
consolidated results of operation and financial condition.
In
December 2007, the FASB issued SFAS No. 160, Non-controlling Interests in
Consolidated Financial Statements – an amendment of Accounting Research
Bulletin No. 51 (“SFAS No. 160”). SFAS No. 160 establishes accounting and
reporting standards for ownership interests in subsidiaries held by parties
other than the parent, the amount of consolidated net income attributable and
to the non-controlling interest, changes in a parent’s ownership
interest, and the valuation of retained non-controlling equity investments when
a subsidiary is deconsolidated.
SFAS No. 160 also establishes disclosure requirements that clearly
identify and distinguish between the interests of the parent and the interests
of the non-controlling owners. SFAS
No. 160 is effective for fiscal years beginning after 15 December 2008. The Company is currently evaluating the potential
impact, if any, of the adoption of SFAS No. 160 on its consolidated results of
operation and financial condition.
3.
Property, Plant and Equipment
|
|
|
Accumulated depreciation
|
|
Net Book Value
|
|
|
Cost
|
|
As at
31 March
2009
|
|
As at
30 June
2008
(Audited)
|
|
|
$
|
|
$
|
|
$
|
|
$
|
|
|
|
|
|
|
|
|
|
Office equipment
|
|
7,891
|
|
4,744
|
|
3,147
|
|
3,712
|
During the
nine month period ended 31 March 2009 the total additions to property, plant
and equipment were $111 (30 June 2008 – $Nil).
4.
Accounts Payable and Accrued Liabilities
Accounts
payable and accrued liabilities are non-interest bearing, unsecured and have
settlement dates within one year.
12
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Notes to Interim Consolidated Financial Statements
(Expressed in U.S. Dollars)
(Unaudited)
31
March 2009
5.
Due
to Related Parties and Related Party Transactions
As at 31 March 2009, the amount due to
related parties includes $1,000 payable to a director of the Company (30 June
2008
–
$1,000). This
balance is non-interest bearing, unsecured and has no fixed terms of repayment.
As at 31 March 2009, the amount due to
related parties includes $10,889 payable to a company owned by a director of
the Company or an officer of PharmaNet (30 June 2008
–
$10,751). This
balance is non-interest bearing, unsecured and has no fixed terms of repayment.
As at 31 March 2009, the amount due to
related parties includes $Nil payable to a company owned by a director of the
Company or an officer of PharmaNet (30 June 2008
–
$1,277). This
balance is non-interest bearing, unsecured and has no fixed terms of repayment.
As at 31 March 2009, the amount due to
related parties includes $1,047,651 payable to PharmaNet (30 June 2008
–
$1,411,131). This balance is non-interest bearing,
unsecured and has no fixed terms of repayment.
During the nine month period ended 31
March 2009, a director of the Company or an officer of PharmaNet, and their
controlled entities were paid or accrued consulting fees and office and
miscellaneous expenses of $23,765
(year ended 30 June 2008 – $79,118, cumulative – $725,970)
and $14,598 (year ended 30 June 2008 - $29,355, cumulative - $47,181)
respectively by the Company.
During the nine month period ended 31
March 2009, a director of the Company or an officer of PharmaNet, and their
controlled entities were paid or accrued rental fees of $Nil by the Company
(year ended 30 June 2008 – $Nil, cumulative – $12,987).
Transactions comprising the amount due
to PharmaNet are as follows:
|
|
For the
nine
month
period ended
31 March
2009
|
|
For the
year
ended
30 June
2008
(Audited)
|
|
|
$
|
|
$
|
|
|
|
|
|
Opening balance, beginning of period
|
|
1,411,131
|
|
1,138,943
|
Funds
transferred to the Company by PharmaNet
|
|
45,875
|
|
319,726
|
Funds transferred to PharmaNet by the Company
|
|
-
|
|
(215,437)
|
Expenses paid by PharmaNet on behalf of the
Company
|
|
110
|
|
690
|
Foreign
currency translation adjustment
|
|
(409,465)
|
|
167,209
|
|
|
|
|
|
Balance as at 31 March 2009 and 30 June 2008
|
|
1,047,651
|
|
1,411,131
|
The average amount due to PharmaNet for
the nine month period ended 31 March 2009 was $1,263,612 (for the year ended 30
June 2008
–
$1,285,705).
13
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Notes to Interim Consolidated Financial Statements
(Expressed in U.S. Dollars)
(Unaudited)
31
March 2009
6.
Capital Stock
Authorized
The
total authorized capital is 300,000,000 common shares with a par value of
$0.001 per common share.
On 29
August 2005, the Company altered its authorized capital by increasing
authorized common shares with a par value of $0.001 from 25,000,000 to
300,000,000 common shares.
Issued
and outstanding
The
total issued and outstanding capital stock is 111,553,740 common shares with a
par value of $0.001 per common share.
i.
On 10 November 2005, the Company completed a private placement of
1,500,000 units for proceeds of $150,000.
Each unit consists of one common share and two share purchase
warrants. Each share purchase
warrant entitles the holder to purchase one additional common share of the
Company for $0.50 per share anytime on or before two years from the date of the
acquisition of the units.
ii.
On 21 July 2006, a former director of the Company returned 20,000,000
common shares of the Company to treasury.
These common shares were cancelled on 21 July 2006.
14
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Notes
to Interim Consolidated Financial Statements
(Expressed
in U.S. Dollars)
(Unaudited)
31 March
2009
7.
Income Taxes
Income tax expense differs from the amount that would result from
applying the federal income tax rate to earnings before income taxes. These differences result from the
following items:
|
|
For the
nine
month period
ended
31 March
2009
|
|
For the
year
ended
30 June
2008
(Audited)
|
|
|
$
|
|
$
|
|
|
|
|
|
Earnings (loss) before income taxes
|
|
(52,551)
|
|
62,296
|
|
|
|
|
|
Federal income tax rates
|
|
34.0%
|
|
34.0%
|
|
|
|
|
|
Income
tax expense (recovery) based on the above rates
|
|
(17,867)
|
|
21,180
|
|
|
|
|
|
Increase
(decrease) due to:
|
|
|
|
|
Non-deductible
expenses
|
|
-
|
|
364
|
Difference
between US and foreign tax rates
|
|
791
|
|
(5,553)
|
Change in
valuation allowance
|
|
(68,220)
|
|
50,918
|
Research and
development tax refund not subject to tax
|
|
-
|
|
(58,761)
|
Foreign
exchange and other
|
|
85,296
|
|
(8,148)
|
|
|
|
|
|
Income tax expense (recovery)
|
|
-
|
|
-
|
The composition of the Company’s deferred tax assets as at 31
March 2009 and 30 June 2008 are as follows:
|
|
As at
31 March
2009
|
|
As at
30 June 2008
(Audited)
|
|
|
$
|
|
$
|
|
|
|
|
|
Net income tax operating loss
carryforward
|
|
1,309,557
|
|
1,541,549
|
|
|
|
|
|
Deferred
tax assets
|
|
416,534
|
|
484,754
|
Less:
Valuation allowance
|
|
(416,534)
|
|
(484,754)
|
|
|
|
|
|
Net
deferred tax asset
|
|
-
|
|
-
|
15
Molecular Pharmacology (USA)
Limited
(A Development Stage
Company)
Notes
to Interim Consolidated Financial Statements
(Expressed
in U.S. Dollars)
(Unaudited)
31 March
2009
The Company has non-capital loss carry-forwards of approximately
$1,309,557 that may be available for tax purposes. The loss carry-forwards are all in
respect of US and Australian operations and expire as follows:
2022
|
20,402
|
2023
|
46,992
|
2024
|
27,717
|
2025
|
14,187
|
2026
|
261,311
|
2027
|
111,155
|
2028
|
77,128
|
2029
|
32,786
|
No expiry
|
717,879
|
|
|
|
1,309,557
|
A full valuation allowance has been recorded
against the potential deferred tax assets associated with all the loss
carry-forwards as their utilization is not considered more likely than not at
this time.
8.
Commitment
On 13 October 2005, t
he Company
entered into a distribution and supply agreement with MPLA (the “Distribution
Agreement”) (Note 1).
The basic terms of the
Distribution Agreement are as follows:
i.
MPLA has granted exclusive
distribution rights to the Company to distribute, market, promote, detail,
advertise and sell certain “Licensed Products”, as defined in the
Distribution Agreement, with metallo-polypeptide analgesic as an active
ingredient, in the United States (excluding its territories and possessions);
ii.
The Company paid MPLA $1,000
upon the date of execution of the Distribution Agreement and is required to pay
$100,000 six months from the date of execution of the Distribution Agreement or
the date that any Licensed Product is available and ready for distribution and
sale in commercial quantities in the United States under the terms of the
Distribution Agreement (the “Commencement Date”), whichever occurs
first;
iii.
The Company is also required
to pay MPLA a royalty of 5% as set out in the Distribution Agreement;
iv.
MPLA will supply all
Licensed Products to the Company under the Distribution Agreement;
v.
MPLA is responsible for
obtaining all necessary regulatory approvals for the licensed product in the
United States; and
vi.
The Distribution Agreement
is for a one year term from the “Commencement Date” and may be
automatically extended by successive one-year periods, unless at least three
months prior to the renewal date, as defined in the Distribution Agreement,
either party advises the other party that it elects not to permit the extension
of the term.
The $100,000 payment to MLPA according to the
terms of the Distribution Agreement has not yet been made and the Company is
currently renegotiating the terms of the Distribution Agreement.
16
Molecular Pharmacology (USA)
Limited
(A Development Stage Company)
Notes to
Interim Consolidated Financial Statements
(Expressed in
U.S. Dollars)
(Unaudited)
31 March 2009
9.
Supplemental Disclosures with Respect to Cash Flows
|
For the period
from the
date of
inception on
14 July
2004
to
31 March
2009
|
|
For the
nine month
period
ended
31 March
2009
|
|
For the
year
ended
30 June
2008
(Audited)
|
|
$
|
|
$
|
|
$
|
|
|
|
|
|
|
Cash paid during the
year for interest
|
-
|
|
-
|
|
-
|
Cash paid during the
year for income taxes
|
-
|
|
-
|
|
-
|
Common shares issued
on acquisition of MPLA
|
16,236
|
|
-
|
|
-
|
Amounts receivable
acquired on recapitalization of the Company
|
2,226
|
|
-
|
|
-
|
Accounts payable
assumed on recapitalization of the Company
|
54,624
|
|
-
|
|
-
|
Due to related party
assumed on recapitalization of the Company
|
1,000
|
|
-
|
|
-
|
10.
Segmented Information
Details
on a geographic basis as at 31 March 2009 are as follows:
|
|
Australia
|
|
U.S.A.
|
|
Total
|
|
|
$
|
|
$
|
|
$
|
|
|
|
|
|
|
|
Assets
|
|
338,474
|
|
(327,410)
|
|
11,064
|
Loss for the period
|
|
(19,765)
|
|
(32,786)
|
|
(52,551)
|
Details
on a geographic basis as at 30 June 2008 are as follows:
|
|
Australia
|
|
U.S.A.
|
|
Total
|
|
|
$
|
|
$
|
|
$
|
|
|
|
|
|
|
|
Assets
|
|
318,283
|
|
(283,685)
|
|
34,598
|
Income (loss) for the year
|
|
138,829
|
|
(76,533)
|
|
62,296
|
17
Item 2. Management’s
Discussion and Analysis of Financial
Condition and Results of Operations
.
THE FOLLOWING ANALYSIS OF THE RESULTS OF OPERATIONS AND
FINANCIAL CONDITION OF MOLECULAR USA FOR THE THIRD QUARTER PERIOD ENDED MARCH
31, 2009 AND SHOULD BE READ IN CONJUNCTION WITH MOLECULAR USA’S FINANCIAL
STATEMENTS, INCLUDING THE NOTES THERETO CONTAINED ELSEWHERE IN THE FORM 10-Q.
Our consolidated financial statements are stated in
United States Dollars and are prepared in accordance with United States
Generally Accepted Accounting Principles.
Overview
We were incorporated in the state of Nevada on May 01,
2002. Up until the fall of 2005, Molecular USA was in the business of mineral
exploration and development of a mineral property.
On October 13, 2005,
Molecular USA entered into a distribution and supply agreement with Molecular Pharmacology
Limited ("
MPLA
"). MPLA is incorporated
under the laws of Australia and at the time was a wholly owned subsidiary
company of PharmaNet Group Limited, an Australian company listed on the
Australian Stock Exchange.
Under the terms of the distribution and supply agreement, Molecular USA
received the exclusive distribution rights to distribute, market, promote,
detail, advertise and sell certain "
Licensed Products
",
as defined in the agreement, with metallo-polypeptide analgesic as an active
ingredient, in the United States (excluding its territories and
possessions).
On May 9, 2006, Molecular USA announced that it has
acquired 100% of the issued and outstanding share capital of MPLA. The transaction was originally announced
by Molecular USA in a press release dated November 29, 2005 and was
subsequently approved by a majority of the stockholders of the Company at a
stockholders meeting held on April 21, 2006. As a result of the transaction,
PharmaNet Group Limited (“
PharmaNet
”),
the former parent company of MPLA, now controls approximately 79% of Molecular
USA's issued and outstanding share capital. The transaction between the parties
closed in escrow with an effective closing date of May 8, 2006. The business of
MPLA is now the business of Molecular USA.
Our Current Business
Molecular USA through its wholly owned subsidiary MPLA
is in the business of developing and commercializing a new analgesic and
anti-inflammatory molecule known as Tripeptofen. Tripeptofen is likely to
appear in a new group of products suitable for the treatment of common
every-day pain. As an analgesic and anti-inflammatory drug, Tripeptofen is
unusual due to its rapid speed of action and its topical or rub-on
application.
The majority of over-the-counter anti-pain and anti-inflammatory
products sold for the treatment of acute localised pain are based on
non-steroidal anti-inflammatory drugs or NSAIDs. The majority of such products
are slow acting and provide only mild pain relief.
The NSAID group has come under additional pressure and
increasing medical alarm, as many drugs in this class have been found to
set-back the recovery of certain conditions and treatments for which they were
marketed. Moreover, NSAIDs are associated with severe gastro-intestinal
side-effects. This has left a niche in an industry under-served by new products
and ingredients.
MPLA's business strategy is to exploit the fast and
locally acting, low side effects, and recovery-enhancing properties of its new
drug group and to market this as a new ingredient, enabling pharmaceutical
companies to develop and market effective and safer products suited to a broad
range of common everyday pain.
18
Licensed Products
Molecular USA has exclusive distribution rights to
distribute, market, promote, advertise and sell certain "Licensed
Products", with metallo-polypeptide analgesic and anti-inflammatory
activity as an active ingredient, in the United States (excluding its
territories and possessions) from its wholly owned subsidiary company MPLA.
The Licensed Products include all products in all dosage
forms, formulations, line extensions and package configurations using or
otherwise incorporating any aspect or production method of metallo-polypeptide
analgesic and anti-inflammatory activity as an active ingredient marketed by
MPLA or its affiliates under the tradename Tripeptofen or any other trade names
or trademarks used by MPLA relating to the product and any improvements to such
formulations or dosages as may hereafter be distributed by MPLA or its affiliates
in the territory during the term of the distribution and supply agreement
between Molecular USA and MPLA for the topical application for human use only,
and specifically excludes:
• dermatological
or cosmetic use, or tissue repair or tissue regeneration effect;
• any
use or application of the Licensed Product in non-human groups or species; and
• Thermalife
cream, presently owned by PharmaNet, the parent company of MPLA.
All Licensed Products must first obtain regulatory
clearance in the United States before they may be marketed and sold by
Molecular USA in that territory. Regulatory approval, commencement of the
Master Drug File (MDF) and market approval are the focus of an ongoing program
expected to continue over the next 18 to 24 months.
MPLA has an exclusive license from Cambridge Scientific
Pty Ltd of Australia. This license is restricted to a "field of use"
defined in the license documentation. Cambridge Scientific may grant other
licenses to third parties outside the "field of use" the subject of
the licenses granted to MPLA.
Patents &
Trademarks
Molecular USA and its subsidiary MPLA, regard their
intellectual property rights, such as copyrights, trademarks, trade secrets,
practices and tools, as important to the success of their company. To protect
their intellectual property rights, Molecular USA relies on a combination of
patent, trademark and copyright law, trade secret protection, confidentiality
agreements and other contractual arrangements with their employees, affiliates,
clients, strategic partners, acquisition targets and others. Effective patent,
trademark, copyright and trade secret protection may not be available in every
country in which the combined company intends to offer its products. The steps
taken by Molecular USA and MPLA to protect their intellectual property rights
may not be adequate. Third parties may infringe or misappropriate the combined
company's intellectual property rights or the combined company may not be able
to detect unauthorized use and take appropriate steps to enforce its rights. In
addition, other parties may assert infringement claims against the combined
company. Such claims, regardless of merit, could result in the expenditure of
significant financial and managerial resources. Further, an increasing number
of patents are being issued to third parties regarding these processes. Future
patents may limit the combined company's ability to use processes covered by
such patents or expose the combined company to claims of patent infringement or
otherwise require the combined company to seek to obtain related licenses. Such
licenses may not be available on acceptable terms. The failure to obtain such
licenses on acceptable terms could have a negative effect on the combined
company's business.
To protect their intellectual property rights, MPLA relies on a
combination of license and patent applications held by Cambridge Scientific Pty
Ltd which includes "Analgesic and
Anti-Inflammatory Composition" comprising USA patent application in
completion plus PCT Provisional Specification having the same name designated
as Serial No. 11/059580
, Cytokine Mediation Composition
PCT/AU2007/000554, Tissue
Disruption Treatment And Composition For Use Thereof United States Of America
Patent Application No. 11/218382 and International Patent Application No.
PCT/AU2006/001288 and COX 2
Inhibitor Application Number WO/2006902207.
19
Marketing
Molecular USA plans to market its Licensed Products,
when approved, through existing pharmaceutical distributors and by
collaborative dealings with major companies active in the United States and
Europe.
In addition, Molecular USA plans to explore
opportunities for direct sales, out-licensing and the integration of the
company’s proprietary anti-inflammatory and analgesic components in products
already distributed through various international markets.
Molecular USA expects that these activities may even
help fund the development costs of the Licensed Products in the United States.
Manufacturing &
Supply
Molecular USA and MPLA have no manufacturing facilities.
MPLA is required to supply Molecular USA with all Licensed Products under the
distribution and supply agreement entered into by the parties in October 2005.
It is likely MPLA will enter into arrangements with various certified
formulation and manufacturers (GMP) of the Licensed Products for clinical trial
and sales purposes. These formulations and the manufacturing facilities must
comply with regulations and current good laboratory practices or cGLPs, and
current good manufacturing practices or cGMPs, enforced by the Food and Drug
Administration (“FDA”).
Molecular USA has not entered into any supply
agreements.
Competition
Molecular USA and MPLA compete in the segment of the
pharmaceutical market that treats pain and inflammation, which is highly
competitive. We face significant competition from most pharmaceutical companies
as well as biotechnology companies that are also researching and selling
products designed to treat pain and inflammation. Many of our competitors have
significantly greater financial, manufacturing, marketing and product
development resources than we do. Large pharmaceutical companies in particular
have extensive experience in clinical testing and in obtaining regulatory
approvals for drugs. These companies also have significantly greater research
capabilities than we do. In addition, many universities and private and public
research institutes are active in neurological research, some in direct
competition with us. These companies, as well as academic institutions,
governmental agencies and other public and private organizations conducting
research, also compete with Molecular USA and MPLA in recruiting and retaining
highly qualified scientific personnel and consultants and may establish
collaborative arrangements with competitors of Molecular USA.
Molecular USA's
competition will be determined in part by the potential indications for which
the MPLA's products are developed and ultimately approved by regulatory
authorities.
Molecular USA knows of
other companies and institutions dedicated to the development of anti-pain and
anti-inflammatory pharmaceuticals similar to those being developed by MPLA and
licensed to Molecular USA. Many of Molecular USA's competitors, existing or
potential, have substantially greater financial and technical resources and
therefore may be in a better position to develop, manufacture and market
pharmaceutical products. Many of these competitors are also more experienced
with regard to preclinical testing, human clinical trials and obtaining
regulatory approvals. The current or future existence of competitive products
may also adversely affect the marketability of Molecular USA's products.
Governmental
Regulation
FDA Regulation
. Pharmaceutical products are subject to
extensive pre- and post-marketing regulation by the Food and Drug Administration (“FDA”),
including regulations that govern the testing, manufacturing, safety, efficacy,
labeling, storage, record-keeping, advertising and promotion of the products
under the Federal Food, Drug and Cosmetic Act and the Public Health Services
Act, and by comparable agencies in most foreign countries. The process required
by the FDA before a new drug may be marketed in the U.S. generally involves the
following: completion of pre-clinical laboratory and animal testing; submission
of an investigational new drug application, or IND, which must become effective
before clinical trials may begin; performance of adequate and well controlled
human clinical trials to establish the safety and efficacy of the proposed
drug’s intended use; and approval by the FDA of a New Drug Application,
or NDA.
The activities required before a pharmaceutical agent
may be marketed in the United States begin with pre-clinical testing. Pre-clinical tests include laboratory
evaluation of potential products and animal studies to assess the potential
safety and efficacy of the product and its formulations. The results of these
studies and other information must be submitted to the FDA as part of an IND
application, which must be reviewed and approved by the FDA before proposed
clinical testing can begin. Clinical trials involve the administration of the
investigational new drug to healthy volunteers or to patients under the
supervision of a qualified principal investigator. Clinical trials are
conducted in accordance with Good Clinical Practices under protocols that
detail the objectives of the study, the parameters to be used to monitor safety
and the efficacy criteria to be evaluated. Each protocol must be submitted to
the FDA as part of the IND application. Further, each clinical study must be
conducted under the auspices of an independent institutional review board. The
institutional review board will consider, among other things, ethical factors
and the safety of human subjects.
Typically, human clinical trials are conducted in three
phases that may overlap. In Phase 1, clinical trials are conducted with a small
number of subjects to determine the early safety profile and pharmacology of
the new therapy. In Phase 2, clinical trials are conducted with groups of
patients afflicted with a specific disease in order to determine preliminary
efficacy, optimal dosages and expanded evidence of safety. In Phase 3, large
scale, multicenter, comparative clinical trials are conducted with patients
afflicted with a target disease in order to provide enough data for the
statistical proof of efficacy and safety required by the FDA and others.
The results of the pre-clinical and clinical testing,
together with chemistry and manufacturing information, are submitted to the FDA
in the form of an NDA for a pharmaceutical product in order to obtain approval
to commence commercial sales. In responding to an NDA, the FDA may grant
marketing approvals, request additional information or further research, or
deny the application if it determines that the application does not satisfy its
regulatory approval criteria. Patient-specific therapies may be subject to
additional risk with respect to the regulatory review process. FDA approval for
a pharmaceutical product may not be granted on a timely basis, if at all, or if
granted may not cover all the clinical indications for which approval is sought
or may contain significant limitations in the form of warnings, precautions or
contraindications with respect to conditions of use.
Satisfaction of FDA premarket approval requirements for
new drugs typically takes several years, and the actual time required may vary
substantially based upon the type, complexity and novelty of the product or
targeted disease. Government regulation may delay or prevent marketing of
potential products for a considerable period of time and impose costly
procedures upon our activities. Success in early stage clinical trials or with
prior versions of products does not assure success in later stage clinical
trials. Data obtained from clinical activities are not always conclusive and
may be susceptible to varying interpretations that could delay, limit or
prevent regulatory approval.
Once approved, the FDA may withdraw the product approval
if compliance with pre- and post-marketing regulatory standards is not
maintained or if problems occur after the product reaches the marketplace. In
addition, the FDA may require post-marketing studies, referred to as Phase 4
studies, to monitor the effect of an approved product, and may limit further
marketing of the product based on the results of these post-market studies. The
FDA has broad post-market regulatory and enforcement powers, including the
ability to levy fines and civil penalties, suspend or delay issuance of
approvals, seize or recall products, or withdraw approvals.
20
Facilities used to manufacture drugs are subject to
periodic inspection by the FDA, Drug Enforcement Agency and other authorities
where applicable, and must comply with the FDA's Current Good Manufacturing
regulations. Failure to comply with the statutory and regulatory requirements
subjects the manufacturer to possible legal or regulatory action, such as
suspension of manufacturing, seizure of product or voluntary recall of a
product. Adverse experiences with the product must be reported to the FDA and
could result in the imposition of market restriction through labeling changes or
in product removal. Product approvals may be withdrawn if compliance with
regulatory requirements is not maintained or if problems concerning safety or
efficacy of the product occur following approval.
With respect to post-market product advertising and
promotion, the FDA imposes a number of complex regulations on entities that
advertise and promote pharmaceuticals, which include, among other things,
standards and regulations relating to direct-to-consumer advertising, off-label
promotion, industry sponsored scientific and educational activities, and
promotional activities involving the Internet. The FDA has very broad
enforcement authority under the Federal Food, Drug and Cosmetic Act, and
failure to abide by these regulations can result in penalties including the
issuance of a warning letter directing the entity to correct deviations from
FDA standards, a requirement that future advertising and promotional materials
be pre-cleared by the FDA, and state and federal civil and criminal
investigations and prosecutions.
Research facilities are subject to various laws and
regulations regarding laboratory practices, the experimental use of animals,
and the use and disposal of hazardous or potentially hazardous substances in
connection with the research in question.
In each of these areas, as above, the government has broad regulatory
and enforcement powers, including the ability to levy fines and civil
penalties, suspend or delay issuance of approvals, seize or recall products,
and withdraw approvals, any one or more of which could have a material adverse
effect upon us.
Other Government Regulations
. In
addition to laws and regulations enforced by the FDA, research of Molecular
USA’s products in the United States are subject to regulation under
National Institutes of Health guidelines, as well as under the Controlled
Substances Act, the Occupational Safety and Health Act, the Environmental
Protection Act, the Toxic Substances Control Act, the Resource Conservation and
Recovery Act and other present and potential future federal, state or local
laws and regulations, as research and development of its products involves the
controlled use of hazardous materials, chemicals, viruses and various
radioactive compounds.
In addition to regulations in the United States,
Molecular USA’s products are subject to a variety of foreign regulations
governing clinical trials and commercial sales and distribution of its Licensed
Products. Whether or not Molecular USA obtains FDA approval for a product,
Molecular USA or its subsidiaries must obtain approval of a product by the
comparable regulatory authorities of foreign countries before it can commence
clinical trials or marketing of the product in those countries. The approval
process varies from country to country, and the time may be longer or shorter
than that required for FDA approval. The requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary greatly from
country to country.
Sarbanes-Oxley Act of 2002
. On July 30, 2002, President Bush signed into
law the Sarbanes-Oxley Act of 2002, or the SOA. SOA imposes a wide variety of
new requirements on both U.S. and non-U.S. companies, that file or are required
to file periodic reports with the Securities and Exchange Commission (the
“SEC”) under the Securities Exchange Act of 1934. Many of these new
requirements will affect Molecular USA and its board of directors. For
instance, under SOA Molecular USA is required to:
-
form an audit committees in compliance with SOA;
-
have Molecular USA’s chief executive office
and chief financial officer are required to certify its financial statements;
-
ensure Molecular USA’s directors and senior
officers are required to forfeit all bonuses or other incentive-based
compensation and profits received from the sale of Molecular USA’s
securities in the twelve month period following initial publication of any of
Molecular USA’s financial statements that later require restatement;
-
disclose any off-balance sheet transactions as
required by SOA;
21
-
prohibit all personal loans to directors and
officers;
-
insure directors, officers and 10% holders file
their Forms 4's within two days of a transaction;
-
adopt a code of ethics and file a Form 8-K when
ever there is a change or waiver of this code; and
-
insure Molecular USA’s auditor is
independent as defined by SOA.
SOA has required us to review our current procedures and
policies to determine whether they comply with the SOA and the new regulations
promulgated thereunder. We will continue to monitor our compliance with all
future regulations that are adopted under the SOA and will take whatever actions
are necessary to ensure that we are in compliance.
Environmental Compliance
The nature of Molecular USA’s and MPLA’s
business does not require special environmental or local government
approval. Molecular USA and MPLA
are compliant with all environmental laws. The cost of such compliance is
minimal for the company.
Employees
Molecular USA currently has no employees and instead
relies on outside contractors.
Immediate Business
Plans
The Company, through its subsidiary MPLA, plans to
continue to pursue the various levels of the international regulatory approval
processes. Applications and product opportunities for Tripeptofen are believed
to be broad and cover a range of commercial fields, each with distinct
pre-market requirements. The international drug development team, global
resources and local know-how will allow MPLA to seek the most time and cost
effective regulatory pathways for each product and market sector.
On commercial development, MPLA will focus on
consolidating the regulatory pathway work in order to prioritise the path to
market. Jeff Edwards will work to set-out the strategies designed to maximize
the multi-jurisdictional capabilities of MPLA's development teams.
Results of Operation
For the Quarter ended March 31, 2009.
Rev
enues
REVENUE
- Molecular USA has not generated any revenues for the
quarter ended March 31, 2009, or since inception.
COMMON STOCK
– Molecular USA has not issued any shares during the most recent quarter. As
of the date April 30, 2009, Molecular USA has 111,553,740 common shares issued
and outstanding.
Expenses
SUMMARY
–
Total expenses were $76,031 for the nine month period ended March 31, 2009. Expenses had decreased during this past quarter
as compared to nine month period ended March 31, 2008 – $147,432. A total
of $1,676,646 in expenses has been incurred by Molecular USA since inception on July
14, 2004 through to March 31, 2009. The decrease in costs over the past
three quarters has occurred as the result of Molecular USA’s wholly owned
subsidiary reducing its consulting and professional fees. The costs can be subdivided into the
following categories.
-
Office Expenses
: $17,230 in office expenses (for rent and
administrative costs) were incurred for the nine month period ended March 31, 2009 as compared to $25,219 for the nine month
period ended March 31,
22
-
2008; while a total of $140,883 was incurred
in the period from inception on
July
14, 2004 to
March 31, 200
9. All contributed
expenses are reported as contributed costs with a corresponding credit to
additional paid-in capital.
-
Consulting and Analysis
Costs
: Molecular USA relies on consultants and other third parties to
conduct the majority of its research.
For the nine month period ended March 31, 2009, $23,765 in
consulting and analysis expenses were incurred as compared to $66,300
during the nine month period ended March 31, 2008.
We have incurred a total of $1,117,405 in consulting and analyst
fees since our inception on July
14, 2004 to March 31, 2009.
-
Advertising and Promotion
Fees
: Molecular USA has spent no money in this area this year. During the nine month period ended March 31, 2009 we spent $0 on advertising and public
relations and $0 for nine month period ended March 31, 2008. A total of $23,739 has been
incurred in this area during the period from inception on July 14, 2004 to March 31, 2009.
-
Professional Fees
: Molecular USA
incurred $28,175 in professional fees for the nine month period ended on March 31, 2009 as compared to $45,536 for the nine month
period ended March 31, 2008. From inception to March
31, 2009, we have incurred a total of $199,857 professional fees mainly
spent on legal and accounting matters.
-
Travel Costs
: Molecular USA
incurred $1,674 in travel
costs for the nine month period ended March 31, 2009 as compared to $6,846
for the nine month period ended March 31,
2008 and $104,240 has been incurred in the period from inception on July 14, 2004 to March 31, 2009. This decrease reflects limited travel
expense this quarter to our North American legal counsel in visiting our
research facilities in Australia.
-
Salaries and Benefit
Costs
: Molecular USA and its subsidiary relies primarily on outside
consultants and not salaried employees. As a result, Molecular USA incurred
$0 in salaries and benefits for the nine month period ended March 31, 2009
and $0 in salaries and benefits during the nine month period ended March
31, 2008. For the period
July
14, 2004 (inception) through March 31, 2009, Molecular USA has spent a total of $44,464
on salaries and benefits.
Molecular USA continues to carefully control its expenses and overall
costs as it moves forward with the development of its new business plan.
Molecular USA does not have any employees and engages personnel through outside
consulting
contracts
or
agreements or other such arrangements
Income Tax Provision
: We have losses carried forward for income tax purpose to March 31, 2009. There are no current or deferred tax
expenses for the period ended March 31, 2009 due to our loss position. We have fully reserved for any benefits
of these losses. The deferred tax
consequences of temporary differences in reporting items for financial
statement and income tax purposes are recognized as appropriate.
Liquidity and Capital
Resources
During the nine month period ended March 31, 2009, Molecular USA satisfied its
working capital needs by borrowing cash from its parent company PharmaNet. As of March 31, 2009, the Company had
cash and cash equivalents on hand in the amount of $4,673 ($21,490 – June
30, 2008) and current payable and accrued liabilities of $12,858 ($26,266
– June 30, 2008). As of March
31, 2009, Molecular USA currently owes its parent company PharmaNet, $1,047,651
and an additional $11,889 to other related parties. Given the proposed business
activities of Molecular USA and its subsidiary, management does not expect that
the current level of cash on hand will be sufficient to fund its operation for
the next twelve month period.
To achieve our goals and objectives for the next 12
months, we plan to raise additional capital through private placements of our
equity securities, proceeds received from the exercise of outstanding options,
future financing from our majority shareholder PharmaNet.
We plan to use any additional funds that we might be
successful in raising for development, as well as for strategic acquisition of
existing businesses that complement our market niche, and general working
capital purposes.
23
If we are unsuccessful in obtaining new capital, our
ability to seek and consummate strategic acquisitions to build our company
internationally, and to expand of our business development and marketing
programs could be adversely affected.
Off-Balance Sheet Arrangement
As of March
31, 2009, Molecular USA did not have any off-balance sheet arrangements.
Research and Development
Since the acquisition of MPLA, Molecular USA has maintained
MPLA’s research and development program to:
-
Refine and prove-up its proprietary active
ingredients and to commence the processes that will lead to the issue of a
Master Drug File registration of its products;
-
Define the mode of action and potential of
Tripeptofen in both in vitro, animal and human studies;
-
Gain Australian regulatory and marketing
approval;
-
Gain European regulatory approval; and
-
Commence application for American regulatory
approval.
MPLA is in the business of developing and
commercializing a new analgesic and anti-inflammatory molecule known as
Tripeptofen. Tripeptofen is likely to appear in a new group of products
suitable for the treatment of common every-day pain. As an analgesic and
anti-inflammatory drug, Tripeptofen is unusual due to its rapid speed of action
and its topical or rub-on application.
During the period Molecular USA, continued to support MPLA
and Cambridge Scientific Pty Ltd in the process of expanding the intellectual
property portfolio. Further details on the scope of these activities is
presented in the section.
Patents & Trademarks.
The first conditions targeted by MPLA will be the
musculoskeletal injuries. The use
of a B-SIM in these markets represents a new approach to one of the
world’s largest over the counter drug markets and includes indications
such as joint inflammation, musculoskeletal pain, overuse and strain injuries,
burns and even surgical and cosmetic procedures. MPLA’s proprietary, industrially
scalable peptide-ligand bond exchange (PLBE) B-SIM manufacturing process
involves the disassociation of proteins, rather than the far more costly
process of assembling B-SIMs one sequence at a time. The patent was lodged in
the name of Cambridge Scientific Pty Ltd; however, Molecular USA holds the
worldwide exclusive license to manufacture, commercialize, market and
distribute topical anti-inflammatory and analgesic products based on the
proprietary MPL-TL compound.
Molecular
USA is still working on the projections regarding the necessary expenditure and
time frame involved in pursuing this research and development program. Any such program will also be subject to
Molecular USA raising the necessary funds to advance such a program.
Capital Expenditure
Commitments
Capital expenditures for the nine month period ended March
31, 2009, amounted to $111. Molecular USA does not anticipate any significant
purchase or sale of equipment over the next 12 months.
Recent Accounting
Pronouncements
In May 2008, the
Financial Accounting Standards Board (the “FASB”) issued SFAS No.
163, “Accounting for Financial Guarantee Insurance Contracts – an
interpretation of FASB Statement No. 60” (“SFAS No. 163”). SFAS No. 163 provides enhanced guidance
on the recognition and measurement to be used to account for
24
premium revenue
and claim liabilities and related disclosures and is limited to financial
guarantee insurance (and reinsurance) contracts, issued by enterprises included
within the scope of FASB Statement No. 60, “Accounting and Reporting by
Insurance Enterprises.” SFAS
No. 163 also requires that an insurance enterprise recognize a claim liability
prior to an event of default when there is evidence that credit deterioration
has occurred in an insured financial obligation. SFAS No. 163 is effective for financial
statements issued for fiscal years and interim periods beginning after 15
December 2008, with early application not permitted. Molecular USA does not expect SFAS No.
163 to have an impact on its consolidated financial statements.
In May 2008, the
FASB issued SFAS No. 162, “The Hierarchy of Generally Accepted Accounting
Principles” (“SFAS No. 162”). SFAS No. 162 is intended to improve
financial reporting by identifying a consistent framework, or hierarchy, for
selecting accounting principles to be used in preparing financial statements
that are presented in conformity with U.S. Generally Accepted Accounting
Principles (“GAAP”) for nongovernmental entities. Prior to the issuance of SFAS No. 162,
GAAP hierarchy was defined in the American Institute of Certified Public
Accountants (“AICPA”) Statement on Auditing Standards No. 69, The
Meaning of Present Fairly in Conformity with Generally Accepted Accounting
Principles (“SAS No. 69”).
SAS No. 69 has been criticized because it is directed to the auditor
rather than the entity. SFAS No.
162 addresses these issues by establishing that the GAAP hierarchy should be
directed to entities because it is the entity, not its auditor, that is
responsible for selecting accounting principles for financial statements that
are presented in conformity with GAAP.
SFAS No. 162 is effective 60 days following the SEC’s approval of
the Public Company Accounting Oversight Board Auditing amendments to AU Section
411, “The Meaning of Present Fairly in Conformity with Generally Accepted
Accounting Principles.”
Molecular USA does not expect SFAS No. 162 to have a material effect on
its consolidated financial statements.
In March 2008, the
FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and
Hedging Activities – an amendment of FASB Statement No. 133”
(“SFAS No. 161”). SFAS
No. 161 is intended to improve transparency in financial reporting by requiring
enhanced disclosures of an entity’s derivative instruments and hedging
activities and their effects on the entity’s financial position,
financial performance, and cash flows.
SFAS No. 161 applies to all derivate instruments within the scope of
SFAS No. 133, “Accounting for Derivative Instruments and Hedging
Activities” (“SFAS No. 133”). It also applies to non-derivative
hedging instruments and all hedged items designated and qualifying as hedges
under SFAS No. 133. SFAS No. 161 is
effective prospectively for financial statements issued for fiscal years
beginning after 15 November 2008, with early application encouraged. Molecular USA is currently evaluating
the new disclosure requirements of SFAS No. 161 and the potential impact on
Molecular USA’s consolidated financial statements.
In December 2007, the FASB issued SFAS No. 141 (revised
2007), “Business Combinations” (“SFAS No. 141(R)”).
SFAS No. 141(R) establishes principles and requirements for how an acquirer
recognizes and measures in its financial statements the identifiable assets
acquired, the liabilities assumed, any noncontrolling interest in the acquiree
and the goodwill acquired. SFAS No. 141(R) also establishes disclosure
requirements to enable the evaluation of the nature and financial effects of
the business combination. SFAS No. 141(R) is effective for fiscal years
beginning after 15 December 2008.
Molecular USA is currently evaluating the potential impact, if any, of
the adoption of SFAS No. 141(R) on its consolidated results of operation and
financial condition.
In December 2007, the FASB issued SFAS No. 160,
“Noncontrolling Interests in Consolidated Financial Statements – an
amendment of Accounting Research Bulletin No. 51” (“SFAS No.
160”). SFAS No. 160
establishes accounting and reporting standards for ownership interests in
subsidiaries held by parties other than the parent, the amount of consolidated
net income attributable and to the noncontrolling interest, changes in a
parent’s ownership interest, and the valuation of retained noncontrolling
equity investments when a subsidiary is deconsolidated. SFAS No. 160 also establishes disclosure
requirements that clearly identify and distinguish between the interests of the
parent and the interests of the noncontrolling owners. SFAS No. 160 is effective for fiscal
years beginning after 15 December 2008.
Molecular USA is currently evaluating the potential impact, if any, of
the adoption of SFAS No. 160 on its consolidated results of operation and
financial condition.
25
Critical Accounting Policies and
Estimates
Our
quarterly financial statements and accompanying notes are prepared in
accordance with generally accepted accounting principles used in the United
States. Preparing financial
statements requires management to make estimates and assumptions that affect
the reported amounts of assets, liabilities, revenue, and expenses. These
estimates and assumptions are affected by management's application of
accounting policies. We believe
that understanding the basis and nature of the estimates and assumptions involved
with the following aspects of our consolidated financial statements is critical
to an understanding of our financials.
Stock-based
compensation
On
February 1, 2006, we adopted the provisions of SFAS No. 123(R),
“
Share-Based Payment
”, which
establishes accounting for equity instruments exchanged for employee
services. Under the provisions of
SFAS No. 123(R), stock-based compensation cost is measured at the grant date,
based on the calculated fair value of the award, and is recognized as an
expense over the employees’ requisite service period (generally the
vesting period of the equity grant).
Before February 1, 2006, we accounted for stock-based compensation
to employees in accordance with Accounting Principles Board Opinion
No. 25, “
Accounting for Stock
Issued to Employees
”, and complied with the disclosure
requirements of SFAS No. 123, “
Accounting for Stock-Based
Compensation
”. We adopted SFAS No. 123(R) using the
modified prospective method, which requires us to record compensation expense
over the vesting period for all awards granted after the date of adoption, and
for the unvested portion of previously granted awards that remain outstanding
at the date of adoption.
Accordingly, financial statements for the periods prior to February 1,
2006 have not been restated to reflect the fair value method of expensing
share-based compensation. Adoption
of SFAS No. 123(R) does not change the way we account for share-based
payments to non-employees, with guidance provided by SFAS No. 123 (as originally
issued) and Emerging Issues Task Force Issue No. 96-18, “
Accounting for Equity Instruments That Are Issued to Other Than
Employees for Acquiring, or in Conjunction with Selling, Goods or Services
”.
Item 3. Quantitative and
Qualitative Disclosures about Market Risk.
Interest Rate Risk
Due to
the short-term nature of our interest bearing assets, which consist primarily
of cash, cash equivalents and restricted cash, we believe that our exposure to
interest rate market risk will not significantly affect our operations.
Foreign Currency Risk
Our head
office and lab operations are based in Australia. Accordingly, we have been
subject to exposure from adverse movements in foreign currency exchange rates.
To date, the effect of changes in foreign currency exchange rates on revenue
and operating expenses has not been material as we have had no revenue and
limited operations. Operating expenses incurred by our foreign subsidiaries
were denominated in local currencies. We have not used financial instruments to
hedge these operating expenses.
Item 4. Controls and Procedures.
(a) Evaluation of Disclosure Controls and Procedures
Based
on the evaluation of Jeff Edwards our President, Chief Executive Officer and
Chief Financial Officer we have concluded that as of March 31, 2009, our
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)
under the Securities Exchange of 1934 (the "
Exchange Act
")
are effective to provide reasonable assurance that the information required to
be disclosed in this quarterly report on Form 10-Q is recorded, processed,
summarized and reported within the time period specified in Securities and
Exchange Commission rules and forms, and that such information is accumulated
and communicated to the Company’s management,
26
including
the Chief Executive Officer and Chief Financial Officer, as appropriate, to
allow for timely decisions regarding required disclosure.
(b) Internal control over financial reporting
Management's
annual report on internal control over financial reporting
Management
is responsible for establishing and maintaining adequate internal control over
financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the
Exchange Act. Our internal control over financial reporting is intended to
provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with U.S. GAAP. Our internal control over financial reporting should include
those policies and procedures that:
-
pertain to the maintenance of records that, in
reasonable detail, accurately and fairly reflect the transactions and
dispositions of our assets;
-
provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in
accordance with applicable GAAP, and that receipts and expenditures are being
made only in accordance with authorizations of management and the Board of
Directors; and
-
provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use or disposition of our
assets that could have a material effect on the financial statements.
Jeff
Edwards, our President, Chief Executive Officer and Chief Financial Officer, has
evaluated the effectiveness of our internal control over financial reporting
and preparation of our quarterly financial statements as of March 31, 2009 and
believe they are effective.
Based
upon their evaluation of our controls, Jeff Edwards, our President, Chief
Executive Officer and Chief Financial Officer, has concluded that there were no
significant changes in our internal control over financial reporting or in
other factors during our last fiscal quarter that have materially affected, or
are reasonably likely to materially affect, our internal control over financial
reporting.
Attestation
report of the registered public accounting firm
This
quarterly report does not include an attestation report of the company's
registered public accounting firm regarding internal control over financial
reporting. Management's report was not subject to attestation by the company's
registered public accounting firm pursuant to temporary rules of the Securities
and Exchange Commission that permit the company to provide only management's
report in this quarterly report.
Changes in internal control over financial reporting
There
were no changes in our internal controls that occurred during the quarter
covered by this report that have materially affected, or are reasonably likely
to materially affect our internal controls.
Changes in Internal Controls
Based on the evaluation as of March 31, 2009, Jeff
Edwards, our President, Chief Executive Officer and Chief Financial Officer has
concluded that there were no significant changes in our internal controls over
financial reporting or in any other areas that could significantly affect our
internal controls subsequent to the date of his most recent evaluation,
including corrective actions with regard to significant deficiencies and
material weaknesses.
28
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
We know of no material, active or pending legal
proceedings against our company, nor are we involved as a plaintiff in any
material proceeding or pending litigation. There are no proceedings in which
any of our directors, officers or affiliates, or any registered or beneficial
shareholder, is an adverse party or has a material interest adverse to our
interest.
Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds.
Recent Sale of Unregistered Securities
Not Applicable.
Use of Proceeds from Unregistered Securities
Not Applicable.
Item 3. Defaults Upon Senior Securities
Not Applicable.
Item 4. Submission of
Matters to a Vote of Security Holders
No matters were submitted to the security holders of
Molecular USA during this quarter.
Item 5. Other Information
No items to disclose.
Item 6. Exhibits
Exhibit
Number
|
Exhibit Title
|
3.1
|
Articles of Incorporation as Amended
(incorporated by reference to exhibit 3.1 to our Form 10-SB Registration
Statement filed on January 23, 2003).
|
3.2
|
Article of Amendment dated August 29, 2005
|
3.3
|
Bylaws as Amended (incorporated by reference to
exhibit 3.2 to our Form 10-SB Registration Statement filed on January 23,
2003).
|
31.1
|
Certificate of CEO as Required by Rule
13a-14(a)/15d-14
|
31.2
|
Certificate of CFO as Required by Rule
13a-14(a)/15d-14
|
32.1
|
Certificate of CEO and CFO as Required by Rule
Rule 13a-14(b) and Rule 15d-14(b) (17 CFR 240.15d-14(b)) and Section 1350 of
Chapter 63 of Title 18 of the United States Code
|
29
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
April
30, 2009.
|
MOLECULAR
PHARMACOLOGY (USA) LIMITED
|
|
BY:
|
/s/ Jeff Edwards
|
|
|
Jeff
Edwards, President, Chief Executive Officer, Chief Financial Officer and a Member
of the Board of Directors
|
|
|
|
|
30
Molecular Pharmacology (PK) (USOTC:MLPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Pharmacology (PK) (USOTC:MLPH)
Historical Stock Chart
From Jul 2023 to Jul 2024